TABLE 2.
Coreceptor usage by HIV-1 viruses isolated using CD8-depleted PBMC versus MDM as target cells
| Virus | Target cells used for isolation | Coreceptor usagea
|
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Control | CCR2b | CCR3 | CCR5 | CCR8 | CXCR4 | CX3CR1 | Gpr1 | Gpr15 | Strl33 | Apj | ||
| MACS1-br | MDM | − | − | − | ++ | − | + | − | − | − | − | − |
| PBMC | − | − | − | +++ | − | +++ | − | − | − | − | − | |
| MACS1-spin | MDM | − | − | − | +++ | − | + | − | − | − | − | − |
| PBMC | − | − | − | +++ | − | +++ | − | − | − | − | + | |
| MACS3-br | MDM | − | − | − | +++ | − | − | − | − | − | − | − |
| PBMC | − | − | + | ++ | + | − | − | − | +/− | − | − | |
a
The pattern of coreceptor usage of viruses isolated using CD8-depleted PBMC or MDM as target cells was determined in Cf2-Luc cells, as described for Fig. 3. Control cells were transfected with CD4 alone. Entry levels were scored as +++ (>50,000 luciferase activity units), ++ (between 30,000 and 50,000 luciferase activity units), + (between 10,000 and 30,000 luciferase activity units), +/− (between 5,000 and 10,000 luciferase activity units), or − (<5,000 luciferase activity units).